Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Leber Congenital Amaurosis Market Size Changed, over the years?

The market for leber congenital amaurosis has seen robust growth in the past few years. The market is set to expand from $1.01 billion in 2024 to roughly $1.07 billion in 2025, with a compound annual growth rate (CAGR) of 6.0%. The notable growth in the earlier period can be credited to enhanced awareness about unusual eye conditions, amplified government support, advancements in diagnostic procedures, the growth of eye research institutions, and initiatives from patient advocacy groups.

How Much Will the Leber Congenital Amaurosis Market Be Worth in 2029?

The market size of Leber congenital amaurosis is predicted to experience substantial growth in the forthcoming years with an expectation to escalate to $1.34 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 5.9%. The surge over the forecast period is ascribed to factors such as escalating investments in gene therapy, an increased incidence of inherited retinal diseases, official authorizations for innovative treatments, wider-ranging clinical trials, and a swelling healthcare expenditure. Key trends anticipated over the forecast period comprise the development of CRISPR-based therapies, heightened collaboration between biotech companies, the creation of personalized medicine, the enlargement of teleophthalmology, and emerging technological innovations in retinal imaging.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22033&type=smp

Which is the Largest Company in the Leber Congenital Amaurosis Market?

Major companies operating in the leber congenital amaurosis market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Invitae Corporation, Novelion Therapeutics Inc., Andelyn Biosciences Inc., CD Genomics Inc., Editas Medicine Inc., MeiraGTx Holdings plc, Sangamo Therapeutics Inc., LKC Technologies Inc., Aldeyra Therapeutics Inc., Asper Biogene OÜ, Allergan Inc., ProQR Therapeutics N.V., GenSight Biologics S.A., Ocugen Inc., IVERIC bio Inc. (formerly Ophthotech Corporation), Atsena Therapeutics Inc., HuidaGene Therapeutics Co. Ltd.

What Are the Main Market Drivers in the Leber Congenital Amaurosis Industry?

The surge in hereditary retinal diseases is set to fuel the expansion of the leber congenital amaurosis (LCA) market. Hereditary retinal diseases (IRDs) are genetic conditions that impact the retina, a light-sensitive tissue at the rear of the eye vital for sight. The rise in these diseases can be linked to improved genetic testing, increased awareness and diagnosis, and longer lifespans. The enhancement in genetic testing has simplified the identification of hereditary retinal diseases, resulting in more cases being discovered. Leber congenital amaurosis aid in unraveling the intricacies of hereditary retinal diseases by exposing gene mutations and disease mechanisms, paving the way for the creation of specific therapies and cures. For instance, data from the UK Parliament’s House of Commons Library, a government agency in the UK, denoted that nearly 25,000 individuals were impacted by hereditary retinal diseases in 2024, marking a yearly rise of 2%. Hence, the escalating prevalence of hereditary retinal diseases is stimulating the growth of the leber congenital amaurosis market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=22033&type=smp

How Is the Leber Congenital Amaurosis Market Segments Structured?

The leber congenital amaurosis market covered in this report is segmented –

1) By Treatment Type: Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices, Other Treatments

2) By Age Of Onset: Congenital Leber Congenital Amaurosis (LCA) (From Birth), Early Childhood Leber Congenital Amaurosis (LCA) (1-5 Years), Late-Onset Leber Congenital Amaurosis (LCA) (6 Years And Above)

3) By Distribution Channel:, Direct Tender, Retail Sales

4) By End User: Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings, Other End Users

Subsegments:

1) By Gene Therapy: RPE65 Gene Replacement Therapy, CRISPR-Based Gene Editing, AAV (Adeno-Associated Virus) Vector Therapy, Emerging Experimental Gene Therapies

2) By Pharmaceutical Drugs: Retinoid-Based Therapies, Neuroprotective Agents, Anti-Inflammatory Drugs, Antioxidant Therapies

3) By Retinal Prosthesis: Implantable Retinal Chips, Artificial Retinal Stimulation Devices, Bionic Eye Technology

4) By Assistive Devices: Low Vision Aids, Screen Readers and Braille Devices, Mobility Aids for Vision Impairment

5) By Other Treatments: Stem Cell Therapy, Optogenetics-Based Treatments, Visual Rehabilitation Programs, Nutritional and Dietary Interventions

What Strategic Trends Are Transforming the Leber Congenital Amaurosis Market?

Key players in the leber congenital amaurosis industry are concentrating on the development of novel solutions, including RNA-based treatments that aid in the enhancement of vision restoration and management of the disease. These treatments use RNA molecules to treat diseases by targeting genetic processes, including mRNA vaccines, siRNA therapies, antisense oligonucleotides, and RNA aptamers. Laboratoires Théa S.A.S., a France-based firm, launched Sepul Bio, a dedicated division aimed at progressing RNA therapies for inherited retinal diseases in January 2025. They specifically target sepofarsen for leber congenital amaurosis 10 (LCA10) and ultevursen for USH2A-associated retinitis pigmentosa. With the successful administration of the first LUNA Phase 2b clinical trial dose for ultevursen, Sepul Bio is in position to make hefty progress in the treatment of these rare genetic diseases.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/leber-congenital-amaurosis-global-market-report

Which Global Regions Offer the Highest Growth in the Leber Congenital Amaurosis Market?

North America was the largest region in the leber congenital amaurosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leber congenital amaurosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22033

This Report Delivers Insight On:

1. How big is the leber congenital amaurosis market, and how is it changing globally?

2. Who are the major companies in the leber congenital amaurosis market, and how are they performing?

3. What are the key opportunities and risks in the leber congenital amaurosis market right now?

4. Which products or customer segments are growing the most in the leber congenital amaurosis market?

5. What factors are helping or slowing down the growth of the leber congenital amaurosis market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model